Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HNF4A | P41235 | 1/20 | 0.49 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5937171 | 0.98 | DHODH (0.55) | DHODHLTB4R2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL9864612 | 0.87 | MEN1 (0.50) | DHODHLTB4R2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL942728 | 0.85 | HNF4A (0.67) | DHODHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL18759613 | 0.84 | HNF4A (0.63) | LTB4R2MEN1KMT2AHNF4ASMN1; SMN2 | |
| SCHEMBL30292805 | 0.84 | HNF4A (0.63) | LTB4R2MEN1KMT2AHNF4ASMN1; SMN2 | |
| SCHEMBL2563193 | 0.84 | BCAT2 (0.65) | DHODHLTB4R2MEN1KMT2AUSP2 | |
| SCHEMBL5937166 | 0.84 | SLC6A3 (0.49) | DHODHLTB4R2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL11554621 | 0.82 | HNF4A (0.61) | LTB4R2MEN1KMT2AHNF4ASMN1; SMN2 | |
| SCHEMBL7245845 | 0.82 | HNF4A (0.49) | LTB4R2MEN1KMT2ALMNAMAPT | |
| SCHEMBL29898486 | 0.81 | PRKAB2 (0.56) | DHODHPRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058372-A1 | N-Benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them | MERCK PATENT GMBH (DE) | 2006-03-16 | — | — | US | claimed |
| CN-1131222-C | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2003-12-17 | — | — | CN | claimed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | claimed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
| EP-0059983-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-06-11 | — | — | EP | claimed |
| EP-0059983-A1 | Substituted biphenyl compounds for use as a medicament | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-09-15 | — | — | EP | claimed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
| EP-0059983-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-06-11 | — | — | EP | disclosed |
| US-4578522-A | CHEMICAL INTERMEDIATES FOR BLOOD LIPID CONTROLLING COMPOUNDS | BURROUGHS WELLCOME CO. | 1986-03-25 | — | — | US | disclosed |
| EP-0059983-A1 | Substituted biphenyl compounds for use as a medicament | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | DHODH 2304/4885LTB4R2 1814/4885PRKAB2 4785/4885 |
| US-20060058372-A1 | N-Benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them | TBXAS1, PCSK9, APOB | DHODH 618/4885LTB4R2 651/4885PRKAB2 3950/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | DHODH 2304/4885LTB4R2 1814/4885PRKAB2 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.